Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011–2014 but increased during 2015–2018 in all age groups. From the...

Full description

Bibliographic Details
Main Authors: Germaine Hanquet, Pavla Krizova, Tina Dalby, Shamez N. Ladhani, J. Pekka Nuorti, Kostas Danis, Jolita Mereckiene, Mirjam J. Knol, Brita A. Winje, Pilar Ciruela, Sara de Miguel, Maria Eugenia Portillo, Laura MacDonald, Eva Morfeldt, Jana Kozakova, Palle Valentiner-Branth, Norman K. Fry, Hanna Rinta-Kokko, Emmanuelle Varon, Mary Corcoran, Arie van der Ende, Didrik F. Vestrheim, Carmen Munoz-Almagro, Juan-Carlos Sanz, Jesus Castilla, Andrew Smith, Birgitta Henriques-Normark, Edoardo Colzani, Lucia Pastore-Celentano, Camelia Savulescu
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2022-01-01
Series:Emerging Infectious Diseases
Subjects:
Streptococcus pneumoniae
pneumococcal infections
13-valent pneumococcal vaccine
10-valent pneumococcal vaccine
15-valent pneumococcal vaccine
20-valent pneumococcal vaccine
Online Access:https://wwwnc.cdc.gov/eid/article/28/1/21-0734_article

Internet

https://wwwnc.cdc.gov/eid/article/28/1/21-0734_article

Similar Items